

Risankizumab-rzaa (Skyrizi®)

Risankizumab-rzaa is a humanized immunoglobulin G1 monoclonal antibody that inhibits interleukin-23 (IL-23).

Resources from Manufacturer

[Medication Guide](#)

[Full Prescribing Information](#)

[Patient Support Program](#)

[Financial Assistance](#)

FDA-Approved Indications and Dosing in Rheumatology

Risankizumab-rzaa is indicated for psoriatic arthritis

Subcutaneous Dosing: Inject 150 mg under the skin at week 0, week 4, and every 12 weeks thereafter

Contraindications

History of serious hypersensitivity to risankizumab-rzaa or any of its excipients

Warnings and Precautions

1. Anaphylaxis or hypersensitivity reaction
2. Infections
3. Tuberculosis
4. Avoid live vaccines while on treatment

Adverse Reactions (≥ 1%)

- Upper respiratory tract infection
- Headache
- Fatigue
- Injection site reactions
- Tinea infections

Medication Strength and Preparations

- Single-dose prefilled syringe: 150 mg/mL (latex-free)
- Prefilled syringe kit (contains 2 single-dose syringes for total dose of 150 mg): 75 mg/0.83mL
- Single-dose prefilled auto-injector (Skyrizi Pen): 150 mg/mL (latex-free)

Medication Administration and Storage

- Store in original carton to protect from light
- Store in refrigerator at 2°C to 8°C (36°F to 46°F) – do not freeze
- Before injecting, allow injection to warm to room temperature for 15 – 90 minutes prior to administration
- Inject subcutaneously into front of thigh or abdomen (avoid injecting within 2 inches of navel)
- Do not administer into tender, bruised, red or hard skin
- Rotate injection sites (\geq 1 inch apart)
- Safe at room temperature (defined as up to 25°C [77°F]) for up to 24 hours
- Does not contain natural rubber latex

Updated June 2023–ARP Practice Committee

DISCLAIMER: The information contained in this biologic reference guide is published by the American College of Rheumatology (“ACR”) for informational purposes only, in furtherance of its educational mission. It is not a substitute for user’s independent medical discretion or decision making, nor a replacement for the manufacturer’s complete prescribing and labeling information, as in effect at the time of use. The information contained herein reflects the conclusions of the individual companies who manufacture the products and not those of the ACR. ACR does not endorse or make any statement regarding the efficacy or safety of any of the listed companies or any of their drugs or other products. ACR specifically disclaims any and all responsibility or liability for the accuracy or completeness of the contents of this reference guide, the use of such information by anyone and/or for the performance of any of the drugs listed in this biologic reference guide (including without limitation, any adverse effects).